Q2 saw 11% TRCV and 4% revenue growth year-over-year, with strong performance in Experience and The Governance Institute segments. Adjusted EBITDA margin held at 27%, and a landmark customer win began revenue recognition. Market uncertainty persists due to industry consolidation.Based on NRC Health…
Q2 saw 11% TRCV and 4% revenue growth year-over-year, with strong performance in Experience and The Governance Institute segments. Adjusted EBITDA margin held at 27%, and a landmark customer win began revenue recognition. Market uncertainty persists due to industry consolidation.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.